The study has enrolled 37 patients (30 of which completed the study) and achieved a sensitivity of 100% and a specificity of 81%.
David Fater, Vicor’s president and CEO, said: “We continue to demonstrate through our clinical efforts that our proprietary PD2i Analyzer has the ability to accurately risk stratify patients into those who require implantable cardioverter defibrillation (ICD) intervention and those who do not.”